Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

How molecular testing can help (and hurt) in the workup of gliomas.

Clark K, Voronovich Z, Horbinski C.

Am J Clin Pathol. 2013 Mar;139(3):275-88. doi: 10.1309/AJCPFO8IIDNBIJ8Y.

2.

Molecular profiling of gliomas--time for a regional service.

Hannan C, Al-Rashid S, Herron B, Conkey D, Harney J, Lyness J, Moss J, Flannery T.

Ulster Med J. 2014 May;83(2):120-1. No abstract available.

3.

Molecular diagnostics of gliomas: state of the art.

Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G.

Acta Neuropathol. 2010 Nov;120(5):567-84. doi: 10.1007/s00401-010-0736-4. Epub 2010 Aug 17. Review.

4.

Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.

Brandner S, von Deimling A.

Neuropathol Appl Neurobiol. 2015 Oct;41(6):694-720. doi: 10.1111/nan.12246. Epub 2015 Jun 10. Review.

PMID:
25944653
5.

[Classification of gliomas. Current progress and perspectives].

Capper D, Reifenberger G.

Nervenarzt. 2015 Jun;86(6):672, 674-6, 678-80, passim. doi: 10.1007/s00115-014-4223-3. German.

PMID:
25989737
6.

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.

7.

Survival and low-grade glioma: the emergence of genetic information.

Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M.

Neurosurg Focus. 2015 Jan;38(1):E6. doi: 10.3171/2014.10.FOCUS12367.

8.

Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.

Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY; POLA Network..

Brain Pathol. 2015 Jul;25(4):418-28. doi: 10.1111/bpa.12227. Epub 2014 Dec 31.

PMID:
25407774
9.

IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.

Shibahara I, Sonoda Y, Kanamori M, Saito R, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Kato S, Ishioka C, Tominaga T.

Int J Clin Oncol. 2012 Dec;17(6):551-61. doi: 10.1007/s10147-011-0323-2. Epub 2011 Oct 6.

PMID:
21971842
10.

Molecular diagnostics of gliomas: the clinical perspective.

Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M.

Acta Neuropathol. 2010 Nov;120(5):585-92. doi: 10.1007/s00401-010-0750-6. Epub 2010 Sep 23. Review.

PMID:
20862485
11.

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.

Draaisma K, Wijnenga MM, Weenink B, Gao Y, Smid M, Robe P, van den Bent MJ, French PJ.

Acta Neuropathol Commun. 2015 Dec 23;3:88. doi: 10.1186/s40478-015-0265-4.

12.

Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.

Ren X, Cui X, Lin S, Wang J, Jiang Z, Sui D, Li J, Wang Z.

PLoS One. 2012;7(3):e32764. doi: 10.1371/journal.pone.0032764. Epub 2012 Mar 12.

13.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

14.

Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.

Olar A, Sulman EP.

Semin Radiat Oncol. 2015 Jul;25(3):155-63. doi: 10.1016/j.semradonc.2015.02.006. Epub 2015 Feb 23. Review.

15.

[Personalized therapy for gliomas].

Wick W, Hau P.

Nervenarzt. 2015 Jun;86(6):692, 694-6, 698-700. doi: 10.1007/s00115-014-4226-0. German.

PMID:
26022855
16.

Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.

Chen L, Voronovich Z, Clark K, Hands I, Mannas J, Walsh M, Nikiforova MN, Durbin EB, Weiss H, Horbinski C.

Neuro Oncol. 2014 Nov;16(11):1478-83. doi: 10.1093/neuonc/nou097. Epub 2014 May 23.

17.

[Genetic alterations and biomarkers for glioma].

Nagane M.

Brain Nerve. 2012 May;64(5):537-48. Review. Japanese.

PMID:
22570067
18.

Molecular markers of gliomas: a clinical approach.

Eoli M, Silvani A, Pollo B, Bianchessi D, Menghi F, Valletta L, Broggi G, Boiardi A, Bruzzone MG, Finocchiaro G.

Neurol Res. 2006 Jul;28(5):538-41. Review.

PMID:
16808886
19.

A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors.

Jiang H, Ren X, Zhang W, Ma J, Sui D, Jiang Z, Cui X, Lin S.

J Neurooncol. 2013 Feb;111(3):367-75. doi: 10.1007/s11060-012-1026-x. Epub 2012 Dec 27.

PMID:
23269453
20.

Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.

Siegal T.

Adv Tech Stand Neurosurg. 2016;(43):91-108. doi: 10.1007/978-3-319-21359-0_4. Review.

PMID:
26508407

Supplemental Content

Support Center